IL-37 As a Potential Biotherapeutics of Inflammatory Diseases.
Interleukin-37
anti-inflammatory
cytokine
immune-mediated inflammatory
inflammatory diseases
rheumatoid
arthritis
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
11
2019
revised:
24
02
2020
accepted:
24
02
2020
pubmed:
30
4
2020
medline:
15
5
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
Interleukin-37 (IL-37) was discovered as a new member of pro-inflammatory IL-1 superfamily. However, further studies suggested that IL-37 plays a critical anti-inflammatory role in innate and adaptive immunity. IL-37 may suppress the inflammatory process via intracellular SMAD family member 3 (SMAD3) and extracellular IL-18 Receptor alpha (IL-18Rα) signaling pathway, respectively. Meanwhile, the abnormal expression of IL-37 was observed in immune-mediated inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis, atherosclerosis, systemic lupus erythematosus, asthma, and multiple sclerosis, which suggest IL-37 is a potential therapeutic target for these diseases. In this review, we summarize the anti-inflammatory mechanism of IL-37 and discuss the critical roles of IL-37 in the pathogenesis of these diseases. Further studies are required to confirm the effectiveness of IL-37 as a novel target for these inflammatory diseases.
Identifiants
pubmed: 32348214
pii: CDT-EPUB-106230
doi: 10.2174/1389450121666200429114926
doi:
Substances chimiques
Anti-Inflammatory Agents
0
IL37 protein, human
0
Interleukin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
855-863Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.